Abstract
Angiogenesis is a key event in cancer progression and therefore a promising target in cancer treatment. Galectin-1, a β-galactoside binding lectin, is up-regulated in the endothelium of tumors of different origin and has been shown to be the target for anginex, a powerful anti-angiogenic peptide with anti-tumor activity. Here we show that when bound to anginex, galectin-1 binds various glycoproteins with hundred- to thousand-fold higher affinity. Anginex also interacts with galectin-2, -7, -8N, and -9N but not with galectin-3, -4, or -9C.
Highlights
Anginex is a 33-mer cytokine-like artificial -peptide that inhibits endothelial cell growth by blocking adhesion and migration of activated endothelial cells leading to angiogenesis in vitro and in vivo [1, 2]
Galectin-1 consists of an ϳ135-amino acid canonical galectin carbohydrate recognition domain (CRD),2 which exists as a
We analyzed the effect of anginex on the carbohydrate binding activity of galectin-1, with the hypothesis that it would act as an inhibitor
Summary
Anginex is a 33-mer cytokine-like artificial -peptide (the sequence is given in supplemental Fig. S1) that inhibits endothelial cell growth by blocking adhesion and migration of activated endothelial cells leading to angiogenesis in vitro and in vivo [1, 2]. With a fixed concentration of a newly designed high affinity tdga-probe [8] (supplemental Fig. S2A) and increasing concentrations of galectin-1, the anisotropy rose from a value
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
